UNITED STATES (Excelsior). Scientists at the Scripps Research Institute in La Jolla, California are successfully testing a new smoking cessation treatment that occurs in rodent tests. The study, published in the journal Science Advances, indicates that scientists gave nicotine-dependent rats an enzyme that breaks down nicotine into the bloodstream before it reaches the brain, rapidly reducing the motivation of the animals to take. the addictive substance, reversed the signs of dependence and prevented them from falling back when they regained access to nicotine.
"This is a new approach that can reduce nicotine addiction without causing cravings and other serious withdrawal symptoms, and it works in the bloodstream, not in the brain, so its side effects should be minimal," says the researcher. director Olivier George, associate professor at Scripps.
Dependence on nicotine prevents smokers from tobacco smoke despite all damage to their health. Researchers estimate that about 60 percent of people who try to get cigarettes come as daily smokers and about 75 percent of daily smokers fall back after smoking cessation. Reversing nicotine dependence by preventing nicotine in tobacco smoke from reaching the brain was considered a promising strategy, but previous efforts have not produced any drugs that sufficiently reduce nicotine levels in the blood to be effective.